Ranked #523 of 8,699 institutional investors
Ra Capital Management, L.P.
Boston, MA
$9.25B
US stock portfolio at live prices · today −$93.7M (−1.00%)
Live prices, last trade 11:32 AM ET
- Value at quarter end (Q3 2026)
- $9.97B
- Change from Q2 2026
- −$1.54B (−13.37%)
- Positions
- 81 · 16 new, 9 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: none$2.76B of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesPBLS 8.78%RYTM 8.18%PCVX 7.05%EWTX 3.67%COAG 3.34%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| PBLS Parabilis Medicines, Inc. | 29,177,964 | $813M | 8.78% | Added +1% |
| RYTM Rhythm Pharmaceuticals, Inc. | 6,666,837 | $757M | 8.18% | Unchanged |
| PCVX Vaxcyte, Inc. | 11,474,599 | $653M | 7.05% | Unchanged |
| EWTX Edgewise Therapeutics, Inc. | 8,392,730 | $339M | 3.67% | Unchanged |
| COAG Hemab Therapeutics Holdings, Inc. | 7,808,627 | $309M | 3.34% | Unchanged |
| SGP SpyGlass Pharma, Inc. | 8,021,117 | $246M | 2.66% | Unchanged |
| TYRA Tyra Biosciences, Inc. | 12,198,625 | $246M | 2.66% | Unchanged |
| SEPN Septerna, Inc. | 5,502,858 | $215M | 2.33% | Reduced −21% |
| IRON Disc Medicine, Inc. | 2,450,221 | $183M | 1.98% | Unchanged |
| XNCR Xencor, Inc. | 5,274,274 | $177M | 1.91% | Unchanged |
| ORKA Oruka Therapeutics, Inc. | 1,554,597 | $146M | 1.58% | Unchanged |
| FRNM Freenome, Inc. | 15,367,270 | $145M | 1.56% | New |
| JANX Janux Therapeutics, Inc. | 11,189,693 | $116M | 1.26% | Unchanged |
| TSHA Taysha Gene Therapies, Inc. | 30,435,190 | $114M | 1.23% | Added +29% |
| AMLX Amylyx Pharmaceuticals, Inc. | 4,279,341 | $111M | 1.20% | New |
| MLYS Mineralys Therapeutics, Inc. | 7,692,750 | $108M | 1.16% | Unchanged |
| CLYM Climb Bio Inc | 10,130,130 | $93.3M | 1.01% | Reduced −10% |
| VOR Vor Biopharma Inc. | 4,503,882 | $89.0M | 0.96% | Added +87% |
| LBRX LB Pharmaceuticals Inc | 2,208,604 | $85.9M | 0.93% | Unchanged |
| SLDB Solid Biosciences Inc. | 12,036,126 | $75.9M | 0.82% | Unchanged |
| PEPG PepGen Inc. | 20,064,545 | $74.5M | 0.81% | Unchanged |
| WVE Wave Life Sciences, Inc. | 26,975,505 | $72.7M | 0.79% | Unchanged |
| ABVX ABIVAX Société Anonyme | 1,030,058 | $71.8M | 0.78% | Reduced −9% |
| ARTV Artiva Biotherapeutics, Inc. | 18,489,293 | $71.6M | 0.77% | Added +3% |
| OBX Obsidian Therapeutics, Inc. | 5,957,103 | $71.5M | 0.77% | New |
| LTGO Latigo Biotherapeutics, Inc. | 5,302,933 | $69.4M | 0.75% | New |
| BCAX Bicara Therapeutics Inc. | 7,255,993 | $64.4M | 0.70% | Unchanged |
| ZLAB Zai Lab Limited | 2,815,543 | $58.4M | 0.63% | Reduced −51% |
| FDMT 4D Molecular Therapeutics, Inc. | 5,049,779 | $53.5M | 0.58% | Unchanged |
| MNPR Monopar Therapeutics Inc. | 667,207 | $45.5M | 0.49% | Unchanged |
| ACRS Aclaris Therapeutics, Inc. | 12,723,026 | $44.2M | 0.48% | Unchanged |
| GERN Geron Corporation | 42,754,145 | $38.9M | 0.42% | Reduced −0% |
| RZLT Rezolute, Inc. | 9,445,039 | $37.6M | 0.41% | Unchanged |
| SPRY ARS Pharmaceuticals, Inc. | 10,860,977 | $34.7M | 0.38% | Unchanged |
| KRSA Korsana Biosciences, Inc. | 892,743 | $33.8M | 0.37% | New |
| DBVT DBV Technologies S.A. | 3,657,644 | $33.4M | 0.36% | New |
| SANA Sana Biotechnology, Inc. | 18,750,000 | $30.9M | 0.33% | Unchanged |
| JBIO Jade Biosciences, Inc. | 1,835,542 | $28.0M | 0.30% | Reduced −50% |
| AGEN Agenus Inc. | 4,122,000 | $25.4M | 0.27% | New |
| EVMN Evommune Inc | 3,494,638 | $24.8M | 0.27% | Unchanged |
| CAPR Capricor Therapeutics, Inc. | 3,014,183 | $23.8M | 0.26% | Added +100% |
| ASMB Assembly Biosciences, Inc. | 1,020,410 | $22.7M | 0.25% | Unchanged |
| SCTX Scribe Therapeutics Inc. | 1,802,178 | $21.9M | 0.24% | New |
| IPSC Century Therapeutics, Inc. | 17,754,430 | $21.7M | 0.23% | Unchanged |
| PRLD Prelude Therapeutics Incorporated | 6,475,882 | $20.8M | 0.22% | Unchanged |
| CCCC C4 Therapeutics, Inc. | 8,194,779 | $20.4M | 0.22% | Added +2% |
| QTTB Q32 Bio Inc. | 2,332,457 | $19.7M | 0.21% | Unchanged |
| SION Sionna Therapeutics, Inc. | 6,456,234 | $18.5M | 0.20% | Reduced −35% |
| AURA Aura Biosciences, Inc. | 2,500,000 | $17.1M | 0.19% | Unchanged |
| SGMT Sagimet Biosciences Inc. | 1,800,000 | $16.3M | 0.18% | New |
| LXEO Lexeo Therapeutics, Inc. | 5,000,000 | $15.9M | 0.17% | Unchanged |
| MIRM Mirum Pharmaceuticals, Inc. | 159,278 | $15.6M | 0.17% | Reduced −50% |
| EDIT Editas Medicine, Inc. | 8,889,000 | $15.3M | 0.17% | Unchanged |
| ACRV Acrivon Therapeutics, Inc. | 12,229,396 | $15.1M | 0.16% | Unchanged |
| BNTC Benitec Biopharma Inc. | 1,850,000 | $14.7M | 0.16% | Unchanged |
| ETRA Electra Therapeutics, Inc. | 1,692,965 | $14.6M | 0.16% | New |
| ALXO ALX Oncology Holdings Inc. | 13,011,849 | $14.0M | 0.15% | Unchanged |
| LENZ LENZ Therapeutics, Inc. | 4,178,823 | $13.1M | 0.14% | Unchanged |
| SPTX Seaport Therapeutics, Inc. | 700,000 | $12.9M | 0.14% | Unchanged |
| NKTX Nkarta, Inc. | 10,805,129 | $12.6M | 0.14% | Unchanged |
| INO Inovio Pharmaceuticals, Inc. | 7,220,384 | $12.5M | 0.14% | New |
| OVID Ovid Therapeutics Inc. | 5,598,200 | $12.4M | 0.13% | Reduced −47% |
| AVR Anteris Technologies Global Corp. | 2,474,076 | $12.3M | 0.13% | Reduced −18% |
| SABS SAB Biotherapeutics, Inc. | 4,401,500 | $12.2M | 0.13% | Unchanged |
| BRVE Braveheart Bio, Inc. | 565,000 | $11.3M | 0.12% | New |
| OKUR OnKure Therapeutics, Inc. | 3,998,333 | $11.0M | 0.12% | Unchanged |
| IKT Inhibikase Therapeutics, Inc. | 6,970,000 | $9.1M | <0.1% | New |
| ALT Altimmune, Inc. | 6,500,000 | $8.9M | <0.1% | Unchanged |
| AVTX Avalo Therapeutics, Inc. | 1,000,000 | $6.8M | <0.1% | Unchanged |
| PALI Palisade Bio, Inc. | 7,124,116 | $6.6M | <0.1% | Unchanged |
| DRUG Bright Minds Biosciences Inc. | 265,000 | $5.6M | <0.1% | Unchanged |
| RANI Rani Therapeutics Holdings, Inc. | 8,500,000 | $4.8M | <0.1% | Unchanged |
| CRBP Corbus Pharmaceuticals Holdings, Inc. | 1,914,788 | $4.3M | <0.1% | New |
| MGNX MacroGenics, Inc. | 1,864,176 | $3.8M | <0.1% | Unchanged |
| ABOS Acumen Pharmaceuticals, Inc. | 20,992,669 | $3.6M | <0.1% | Unchanged |
| EQ Equillium, Inc. | 2,317,741 | $2.7M | <0.1% | Reduced −25% |
| ACET Adicet Bio, Inc. | 932,624 | $2.3M | <0.1% | Unchanged |
| STOK Stoke Therapeutics, Inc. | 73,607 | $2.0M | <0.1% | New |
| STRO Sutro Biopharma, Inc. | 210,934 | $1.9M | <0.1% | New |
| FTH Faeth Therapeutics, Inc. | 205,060 | $1.8M | <0.1% | Reduced −72% |
| PTN Palatin Technologies, Inc. | 62,124 | $309K | <0.1% | Unchanged |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| BCRX BioCryst Pharmaceuticals, Inc. | 15,827,186 | $116M |
| NTLA Intellia Therapeutics, Inc. | 4,526,926 | $46.0M |
| DFTX Definium Therapeutics, Inc. | 1,500,000 | $43.7M |
| AKTS Aktis Oncology, Inc. | 1,314,405 | $21.6M |
| WAY Waystar Holding Corp. | 529,400 | $14.2M |
| BIOA BioAge Labs, Inc. | 1,671,648 | $7.5M |
| CRVS Corvus Pharmaceuticals, Inc. | 450,000 | $4.4M |
| HOWL Werewolf Therapeutics, Inc. | 2,387,744 | $2.2M |
| KPTIQ Karyopharm Therapeutics Inc. | 1,917,354 | $65K |